WEGO威高品牌怎么样 申请店铺

外推网助力WEGO威高品牌出海！将品牌入驻外推网，定制WEGO威高品牌推广信息，可以显著提高WEGO威高产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

威高集团有限公司始建于1988年，以一次性医疗器械和药业为主业，大力发展房地产业，壮大旅游餐饮服务业，稳健发展金融业，实行多业并举，联动发展。下辖医用制品、血液净化、骨科、生物科技、药业、心内耗材、医疗商业、房地产、金融等9个产业集团、50多个子公司，医疗器械和药品主要有输注耗材、输血器材、心内耗材、留置针及各种异型针、血液净化设备及耗材、骨科材料、手术设备及附件、创伤护理、手术机器人、微创器械及设备、ICU产品及附件、大容量注射液及其它药品、肾科产品、生物诊断试剂、手术缝合线、牙种植体、感控设备及耗材、PVC及非PVC原料等50多个系列，500多个品种、8万多个规格, 总资产400多亿元，占地600多万平方米，净化车间260多万平米。成为全球品种齐全、值得信赖的医疗系统解决方案制造商。积极进入医疗健康和服务领域，开展肾透析服务，在全国建有数十家肾透析中心。集团控股子公司山东威高集团医用高分子制品股份有限公司为香港上市公司。

建立了30多家研发中心或联合实验室，并在北京、天津、长春、深圳设立研发机构，拥有研发和管理人员4000人。现拥有发明专利150多项，自主知识产权产品600多项。

威高坚持实施“走出去”战略，加强国际合作。2004年，威高股份在香港创业板上市，2010年转主板上市，开辟了融资新平台。先后与世界银行、美国美敦力公司、日本日机装株式会社、日本泰尔茂株式会社、美国真视觉公司、韩国IT公司等企业建立了战略合作关系，并在美国、日本、英国、德国、法国建有研发中心，吸收全球医疗技术，提高自主创新能力。

威高将始终坚持“开拓创新，求实巩固”的建厂方针，秉承“偕同白衣使者，开创健康未来”的使命，树立良心、诚心、忠心的核心价值观，坚持“一个中心、三个调整”的战略方针，积极转变经济增长方式，持续提高自主创新能力，更高层次地整合研发资源，坚持研发高科技新产品，力争在医疗器械和药业等关键领域取得技术和研发的重大突破；立足国内和国际两个市场，以国际合作为契机，逐步实现管理理念、经营机制、人力资源、技术、产品、市场等对接，强强合作，融合共进，提高企业的核心竞争力，打造全球化公司。

Founded in 1988, Weigao Group Co., Ltd. takes disposable medical equipment and pharmaceutical industry as its main business, vigorously develops the real estate industry, strengthens the tourism and catering service industry, develops the financial industry steadily, implements the multi industry simultaneous development and linkage development. It has nine industrial groups and more than 50 subsidiaries, including medical products, blood purification, orthopedics, biotechnology, pharmaceutical industry, intracardiac consumables, medical commerce, real estate, finance, etc. medical devices and drugs mainly include infusion consumables, blood transfusion equipment, intracardiac consumables, retention needles and various types of needles, blood purification equipment and consumables, orthopedic materials, surgical equipment and accessories, trauma care More than 50 series, more than 500 varieties and more than 80000 specifications, including surgical robots, minimally invasive devices and equipment, ICU products and accessories, large volume injection and other drugs, nephrology products, biological diagnostic reagents, surgical sutures, dental implants, sensing equipment and consumables, PVC and non PVC raw materials, with a total asset of more than 40 billion yuan, covering an area of more than 6 million square meters, and a purification workshop of more than 2.6 million square meters. Become a global manufacturer of a wide range of reliable medical system solutions. We have actively entered the field of medical health and services, carried out renal dialysis services, and established dozens of renal dialysis centers throughout the country. Shandong Weigao group medical polymer products Co., Ltd., a holding subsidiary of the group, is a Hong Kong listed company. More than 30 R & D centers or joint laboratories have been established, and R & D institutions have been set up in Beijing, Tianjin, Changchun and Shenzhen, with 4000 R & D and management personnel. Now it has more than 150 invention patents and more than 600 independent intellectual property products. Weigao adheres to the strategy of "going global" and strengthens international cooperation. In 2004, wego shares were listed on the Hong Kong Growth Enterprise Board, and in 2010, it was listed on the main board, opening up a new financing platform. It has successively established strategic cooperative relations with the world bank, Medtronic company of the United States, Japan Jizhuang Co., Ltd., talmao company of Japan, zhenvision company of the United States, it company of Korea and other enterprises, and has established R & D centers in the United States, Japan, the United Kingdom, Germany and France to absorb global medical technology and improve the ability of independent innovation. Weigao will always adhere to the factory building policy of "pioneering innovation, seeking truth and consolidating", the mission of "working with the emissary of white clothes to create a healthy future", establish the core values of conscience, sincerity and loyalty, adhere to the strategic policy of "one center, three adjustments", actively change the mode of economic growth, continuously improve the ability of independent innovation, integrate R & D resources at a higher level, and firmly Hold the research and development of new high-tech products, strive to make major breakthroughs in technology and R & D in key areas such as medical devices and pharmaceutical industry; based on domestic and international markets, take the opportunity of international cooperation, gradually realize the docking of management concept, business mechanism, human resources, technology, products, market, etc., strengthen cooperation, integrate and advance together, improve the core competitiveness of enterprises, and create Globalization Company.

本文链接： https://brand.waitui.com/a4084d2ef.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加